Carrie L. Bourdow

Carrie L. Bourdow

President and Chief Executive Officer

Ms. Bourdow was appointed President, Chief Executive Officer, and member of the Trevena Board of Directors in October 2018. She has served in various senior positions at Trevena since May 2015. She joined the Company as Chief Commercial Officer and was appointed Executive Vice President and Chief Operating Officer in January 2018. Prior to joining Trevena, Ms. Bourdow was Vice President of Marketing at Cubist Pharmaceuticals, Inc., from 2013 until its acquisition by Merck & Co. (MRK), Inc. in January 2015.  At Cubist, Ms. Bourdow led launch strategy, marketing, reimbursement, and operations for five acute care hospital pharmaceuticals totaling over $1 billion in annual revenues. Prior to Cubist, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across multiple therapeutic areas. Since June 2017, she has served on the board of Nabriva Therapeutics plc. (NBRV), a publicly traded biopharmaceutical company. In February 2020, Ms. Bourdow joined the board of Sesen Bio (SESN), a public biopharmaceutical company.

Scott Applebaum

Scott Applebaum

Chief Legal and Compliance Officer and SVP of Regulatory Affairs

Mr. Applebaum joins Trevena with extensive experience providing legal counsel and regulatory guidance to biopharmaceutical companies in a variety of roles across several organizations. He began his biopharmaceutical career over two decades ago at Bristol-Myers Squibb, where he served in various legal and compliance roles. He subsequently joined Shire Pharmaceuticals as Senior Vice President, where he held leadership roles in multiple functions, including SVP of Legal, SVP of Global Regulatory Affairs & Quality Assurance and SVP of the Global Neuroscience Business Unit where he led the successful launch of Shire’s flagship and market-leading ADHD product in multiple countries. Mr. Applebaum’s experience with high growth biopharmaceutical companies includes his role as General Counsel and Corporate Secretary of Vitae Pharmaceuticals where he played a key role in the sale of Vitae to Allergan plc, as well as Chief Legal Officer of Medgenics. Most recently, Mr. Applebaum was President of Context Therapeutics, a privately held biopharma company dedicated to discovering novel compounds for the treatment of hormone responsive cancers. Mr. Applebaum received a B.S.E. in Finance and Accounting from the Wharton School of the University of Pennsylvania and a J.D. from the Stanford Law School.

Mark A. Demitrack, MD

Mark A. Demitrack, MD

Senior Vice President, Chief Medical Officer

Dr. Demitrack joined Trevena as Senior Vice President and Chief Medical Officer in May 2018. He is a board-certified psychiatrist with over thirty years of experience in both academic and industry settings in clinical neuroscience research. Prior to joining Trevena, Dr. Demitrack was Vice President of Clinical Strategy at Roivant Sciences from May 2017 to May 2018. From July 2003 to May 2017, Dr. Demitrack served as Vice President and Chief Medical Officer of Neuronetics, Inc., where he led the clinical development introducing the NeuroStar TMS Therapy System. Prior to this, Dr. Demitrack was Assistant Vice President for Global Medical Affairs in Neuroscience at Wyeth Pharmaceuticals where he was responsible for post-marketing clinical development of the Effexor XR brand. Dr. Demitrack also served as Medical Director of the New Antidepressant Team at Lilly Research Laboratories where he led the registration clinical development and the initial NDA submission program for the antidepressant, duloxetine (Cymbalta). Prior to his industry career, Dr. Demitrack was a faculty member of the Department of Psychiatry at the University of Michigan Medical School, where he directed the Michigan Eating Disorders Program and received federal grant funding in clinical research studying the neuroendocrine pathophysiology of eating disorders and the idiopathic conditions chronic fatigue syndrome and fibromyalgia. Dr. Demitrack received a BA in Physics from Columbia University and his MD from the Robert Wood Johnson Medical School in New Jersey. He completed his psychiatry residency training at the University of California-San Francisco and completed a research fellowship in clinical neuroendocrinology at the National Institute of Mental Health. Dr. Demitrack is a Fellow of the American Psychiatric Association and a Member of the American College of Neuropsychopharmacology. Dr. Demitrack has published over 100 articles, book chapters and reviews on the pathophysiology and treatment of mood disorders and related conditions.

Barry Shin

Barry Shin

Senior Vice President, Chief Financial Officer

Barry Shin joined Trevena as Senior Vice President and Chief Financial Officer in June 2019. Mr. Shin brings over 17 years of investment banking and corporate advisory experience, focused on the biopharmaceutical sector, and has advised numerous biopharmaceutical companies through merger and acquisition (M&A) and financing transactions. Prior to joining Trevena, he was Managing Director in the Healthcare Investment Banking Group at Mizuho Securities. Prior to joining Mizuho Securities, he was a Managing Director in Guggenheim Securities’ Healthcare Investment Banking Group from 2012 to 2017. From 2005 to 2012, he served in positions of increasing responsibility within the Healthcare Investment Banking Group of Piper Jaffray. From 2001 to 2005, he advised healthcare and technology companies in financing and M&A transactions as a corporate attorney. Mr. Shin received a B.Sc. and joint J.D. / M.B.A. from the University of Toronto.

Robert T. Yoder

Robert T. Yoder

Senior Vice President, Chief Business Officer

Mr. Yoder was appointed Senior Vice President and Chief Business Officer in December 2018. He joined Trevena as Vice President of Commercial Operations and Sales in June 2018. Prior to this, he served as Senior Vice President and Head of Global Commercial Operations, Alliance Management and IT at Orexigen Therapeutics, a biopharmaceutical company, from March 2015 through June 2018. While at Orexigen, Mr. Yoder built the commercial infrastructure with a focus on innovative, efficient, and effective business process and architecture. Additionally, he led external business development efforts that delivered 11 partnership deals spanning 67 countries. Prior to joining Orexigen, Mr. Yoder spent 28 years at Merck, where he held various roles of increasing responsibility across global business operations and commercial functions. In several of these roles, he was responsible for oversight and execution of large-scale initiatives including integration following acquisitions and led a range of organizational design and corporate change initiatives. Mr. Yoder received his Bachelor of Science degree in biology from Dickinson College and earned his Master of Business Administration from Emory University.

Joel S. Solomon, Esq.

Joel S. Solomon, Esq.

Vice President, Legal & Compliance & Corporate Secretary

Joel Solomon has been with Trevena since February 2015 and currently serves as the Company’s Vice President, Legal & Compliance and Corporate Secretary. Mr. Solomon brings more than 23 years of legal experience predominantly focused on the pharmaceutical and medical device industry, with an expertise in mergers and acquisitions, licensing, corporate governance, finance, fundraising, and complex international transactions. Prior to joining Trevena, Mr. Solomon led the business and finance practices at different law firms and served as outside General Counsel to several public and privately-held companies in a variety of industries. Before his legal career, Mr. Solomon was an advertising copywriter and account executive for a Boston-based advertising and public relations firm where he created marketing and advertising campaigns for Fortune 500 companies. Mr. Solomon obtained his B.S. cum laude from Boston University and his J.D. from The Dickinson School of Law of The Pennsylvania State University.

Linda Wase, MD

Linda Wase, MD

Vice President, Clinical Operations and Medical Affairs

Dr. Wase joined Trevena as Vice President, Medical Affairs in February 2018. She is board-certified in Internal Medicine with extensive pharmaceutical industry experience across a broad number of therapeutic areas. Prior to joining Trevena she provided Medical Affairs consulting services from 2015 to 2018 for a variety of companies building their medical affairs capabilities, including Trevena. She was Vice President, Medical Services and Customer Engagement at GlaxoSmithKline from 2012 to 2015 where she led in-house and field-based organizations responsible for scientific engagement with health care professionals. From 2007 until acquisition by Pfizer in 2011 she served as Vice President, Medical Affairs at King Pharmaceuticals where she was responsible for building a Medical Affairs organization and strategies to support the developing portfolio of abuse-deterrent opioid medications. Dr. Wase also spent 19 years at Bristol-Myers Squibb in leadership roles in Medical Affairs, Scientific Affairs and Marketing. Dr. Wase received a BS in Biology from Union College and her M.D. from New York Medical College. Her Internal Medicine residency training was completed in a joint program involving Overlook Hospital in New Jersey and Columbia University Hospital in New York City. Dr. Wase is a Fellow of the American College of Physicians.

Michael S. Kramer

Michael S. Kramer

Vice President, Scientific Operations & Alliance Management

Mike Kramer joined Trevena in 2013 and currently serves as Vice President, Scientific Operations and Alliance Management. Mr. Kramer has over 20 years of experience in pharmaceutical and biotechnology research and development overseeing nonclinical development, CMC and project management activities. Prior to joining Trevena, Mr. Kramer served as Director of Nonclinical Pharmacology and Toxicology at Synergy Pharmaceuticals where he worked on the development of novel small molecules/peptides for the treatment of gastrointestinal diseases. Prior to that role, Mr. Kramer held roles of increasing responsibility within Nonclinical Development and Safety at Neuron Therapeutics, Palatin Technologies and Promedior, developing drugs in multiple therapeutic areas ranging from fibrotic disease to CNS conditions. Mr. Kramer received his B.S. in Biology from The Pennsylvania State University and earned his M.S. in Biological Sciences/Molecular Biology from Drexel University.

Katrine Sutton

Katrine Sutton

Vice President, Finance Planning & Analysis

Katrine Sutton joined Trevena in July 2019 and currently serves as the Company's Vice President of Finance, Planning & Analysis where she is responsible for financial forecasting, strategic budgets and accounting operations. Ms. Sutton brings more than 15 years of experience in finance and accounting for life science companies. Prior to joining Trevena, Ms. Sutton served as Vice President, Finance and Accounting at Synergy Pharmaceuticals from 2015 through 2019. Prior to joining Synergy, Ms. Sutton spent 10 years at Shire Pharmaceuticals where she held various roles of increasing responsibility across regional and global business units. She was responsible for the finance support of commercial launches, mergers and acquisitions, financial forecasting, process improvements and resource allocations. Ms. Sutton began her career as an auditor with KPMG. Ms. Sutton earned a B.S. in Accounting from the University of Richmond and is a Certified Public Accountant.

Michael J. Fossler, Pharm. D., Ph. D., F.C.P.

Michael J. Fossler, Pharm. D., Ph. D., F.C.P.

Vice President, Clinical Development and Quantitative Sciences

Michael J. Fossler is Vice-President, Clinical Development and Quantitative Sciences, at Trevena, Inc. From 1995 to 2000, Dr. Fossler was employed by the FDA as a clinical pharmacology reviewer in the Division of Metabolic and Endocrine Drug Products.  In 1998, he was promoted to Senior Reviewer, and joined the Pharmacometrics group at FDA, where he was responsible for reviewing and performing population PK/PD analyses. He left the Agency in 2000 and joined the Clinical Pharmacokinetics Group at DuPont Pharmaceuticals, where he had major responsibility for PK/PD analyses in the cardiovascular and anti-inflammatory areas. In November, 2001, he joined GlaxoSmithKline, where he continued to work in the cardiovascular area, and eventually headed a group of nine pharmacometrics scientists. He left GSK in 2015 to assume his present role at Trevena, Inc., where he heads up clinical pharmacology, clinical operations, biostatistics, programming and data management. He received a Pharm. D. (1992) and Ph. D. (1995) degrees from the University of Maryland. Dr. Fossler is a Fellow of the American Foundation for Pharmaceutical Education, a Fellow of the American College of Clinical Pharmacology, a past President of the College and is an Honorary Regent.  He holds adjunct faculty appointments at the University of Maryland School of Pharmacy, Mercer University, and the University of North Texas, and is on the faculty of the University of California’s American Course on Drug Development and Regulatory Science.